卓翼科技(002369.SZ):上元資本及其一致行動人合計持股降至4.995%
格隆匯3月6日丨卓翼科技(002369.SZ)公佈,公司於2020年3月6日接到公司持股5%以上股東深圳市上元資本管理有限公司(“上元資本”)及其一致行動人深圳市上元星暉電子產業股權投資基金企業(有限合夥)(“上元星暉”)遞交的《深圳市卓翼科技股份有限公司簡式權益變動報告書》及相關資料。
2018年11月13日至2020年3月6日期間,上元資本通過深圳證券交易所以集中競價交易方式合計賣出公司股份1582.8979萬股,佔公司總股本比例為2.7390%,此次減持後,上元資本及其一致行動人上元星暉合計持有公司股份2886.644萬股,佔公司總股本比例為4.9950%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.